Rivaroxaban's Vascular Dose for the Neurovascular Clinician

Authors

Ji Y. Chong, Stroke Center, New York Medical College, Westchester Medical Center, Valhalla, NY, USA.
Kalimullah Jan, Neurovascular Fellow, New York Medical College, Westchester Medical Center, Valhalla, NY, USA. Kohatian3659@yahoo.com.

Author Type(s)

Faculty

DOI

10.1186/s41016-024-00373-4

Journal Title

Chinese Neurosurgical Journal

First Page

20

Document Type

Letter to the Editor

Publication Date

7-3-2024

Department

Neurology

Abstract

Rivaroxaban, a direct oral anticoagulant, has proven efficacy and safety at its standard dose in the treatment and prevention of various vascular conditions. These include the treatment of venous thromboembolism and stroke prevention in non-valvular atrial fibrillation. A "very low" vascular dose of rivaroxaban, when combined with low-dose aspirin, has been demonstrated to reduce major adverse cardiovascular events, including stroke, in both acute and chronic coronary syndrome. The combination of rivaroxaban and low-dose aspirin could potentially offer an additional strategy for stroke prevention in selected non-atrial fibrillation patients who are at a high risk of stroke.

Recommended Citation

Chong, J. Y., & Jan, K. (2024). Rivaroxaban's Vascular Dose for the Neurovascular Clinician. Chinese Neurosurgical Journal, 10 (1), 20. https://doi.org/10.1186/s41016-024-00373-4